The intravenous and oral pharmacokinetics of afoxolaner used as a monthly chewable antiparasitic for dogs

Veterinary Parasitology

Volumn 201, Issue 3-4, 2014, Pages 190-197

  Letendre, Laura ^a   Huang, Rose ^a   Kvaternick, Valerie ^a   Harriman, Jay ^a   Drag, Marlene ^a   Soll, Mark ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Afoxolaner; Dose efficacy; Isoxazoline; Pharmacokinetics; PK; Protein binding

Indexed keywords

AFOXOLANER; DRUG METABOLITE; ISOXAZOLINE DERIVATIVE; NEXGARD; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BEAGLE; COMPARTMENT MODEL; CONTROLLED STUDY; CTENOCEPHALIDES; DERMACENTOR VARIABILIS; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; FEMALE; FLEA BITE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RHIPICEPHALUS SANGUINEUS; TICK INFESTATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

CANIS FAMILIARIS; CTENOCEPHALIDES FELIS; DERMACENTOR VARIABILIS; RHIPICEPHALUS SANGUINEUS;

AFOXOLANER; DOSE EFFICACY; ISOXAZOLINE; PHARMACOKINETICS; PK; PROTEIN BINDING;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; ANTIPARASITIC AGENTS; AREA UNDER CURVE; DOG DISEASES; DOGS; FEMALE; FLEA INFESTATIONS; ISOXAZOLES; MALE; NAPHTHALENES; PROTEIN BINDING; TICK INFESTATIONS;

EID: 84898057079     PISSN: 03044017     EISSN: 18732550     Source Type: Journal    
DOI: 10.1016/j.vetpar.2014.02.021     Document Type: Article

References (23)

1. Beugnet F., Franc M. Insecticide and acaricide molecules and/or combinations to prevent pet infestation by ectoparasites. Trends Parasitol. 2012, 28:267-279.
2. Chen, K-H., Lin, K-Y., 2010. ML-3,663,925: In Vitro Permeability and Combination Screen Assays. MDS Pharma Services. Unpublished data.
3. Davies B., Morris T. Physiological parameters in laboratory animals and humans. Pharm. Res. 1993, 10:1093-1096.
4. Drag M., Saik J., Jay Harriman J., Larsen D. Safety evaluation of orally administered afoxolaner in eight-week-old dogs. Vet. Parasitol. 2014, 201:198-203.
5. Dumont P., Blair J., Fourie J., Chester T., Larsen D. Evaluation of the efficacy of Afoxolaner against two European dog tick species: Dermacentor reticulatus and Ixodes ricinus. Vet. Parasitol. 2014, 201:216-219.
6. Ensley S. Veterinary Toxicology Basic and Clinical Principles. Imidacloprid 2012, 505-507. Academic Press, (Chapter 44), printed in USA. second ed. R.C. Gupta (Ed.).
7. FDA guideline for validated bioanalytical methods. http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf.
8. 3H]isoxazoline insecticide. Chem. Res. Toxicol. 2013, 26:514-516.
9. Gupta R. Veterinary Toxicology Basic and Clinical Principles. Fipronil 2012, 502-504. Academic Press, (Chapter 43), printed in the USA. second ed.
10. Holmstrom S.D., Totten M.L., Newhall K.B., Qiao M., Riggs K.L. Pharmacokinetics of spinosad and milbemycin oxime administered in combination and separately per os to dogs. J. Vet. Pharmacol. Ther. 2012, 35:351-364.
11. Hummel J., McKendrick S., Brindley C., French R. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm. Stat. 2009, 8:38-49.
12. Hunter J., Dumont P., Chester T., Young D., Fourie J., Larsen D. Evaluation of the curative and preventive efficacy of a single oral administration of afoxolaner against cat flea Ctenocephalides felis infestations on dogs. Vet. Parasitol. 2014, 201:207-211.
13. Jenkins A.J., Cone E.J. Pharmacokinetics: Drug Absorption Distribution and Elimination 1998, Intramural Research Program, National Institute on Drug Abuse/CRC Press LLC, Nation Institutes of Health, Baltimore, MD, (Chapter 3).
14. Maddison J.E., Page S.W., Church D.B. Small Animal Clinical Pharmacology 2008, Elsevier, 228 pp. second ed.
15. Mitchell E., Dorr P., Everett W., Chester T., Larsen D. Efficacy of Afoxolaner against Dermacentor variabilis ticks in dogs. Vet. Parasitol. 2014, 201:220-222.
16. Ozoe Y., Asahi M., Ozoe F., Nakahira K., Mita T. The antiparasitic isoxazoline A1443 is a potent blocker of insect ligand-gated chloride channels. Biochem. Biophys. Res. Commun. 2010, 391:744-749.
17. Rowland M., Tozer T.N. Clinical Pharmacokinetics, Concepts and Applications 1995, 168-169. Lippincott Williams and Wilkins. third ed.
18. Shoop W., Hartline E., Gould B., Waddell M., McDowell R., Kinney J., Lahm G., Long J., Xu M., Wagerle T., Jones G., Dietrich R., Cordova D., Schroeder M., Rhoades D., Benner E., Confalone P. Discovery and mode of action of afoxolaner, a new isoxazoline parasiticide for dogs. Vet. Parasitol. 2014, 201:179-189.
19. Toutain P.L., Bousquet-Melou A. Volumes of distribution. J. Vet. Pharmacol. Ther. 2004, 27:441-453.
20. USDA, 2008. http://awic.nal.usda.gov/government-and-professional-resources/federal-laws/animal-welfare-act.
21. Wenkui L., Zhang J., Tse F.L.S. Handbook of LC-MS Bioanalysis. Best Practices, Experimental Protocols and Regulations 2013, John Willey & Sons, New Jersey, 673 pp., printed in Canada.
22. Woods D.J., Vaillancourt V.A., Wendt J.A., Meeus P.F. Discovery and development of veterinary antiparasitic drugs: past, present and future. Future Med. Chem. 2011, 3:887-896.
23. Wu C.-Y., Benet L.Z. Predicting drug disposition via application of BSC: transport/absorption? Elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 2005, 22:11-23.